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Objectives: To determine the safety and efﬁcacy of stoss therapy on vitamin D levels over a 12 month period in children with cystic ﬁbrosis and
vitamin D deﬁciency (b75 nmol/L).
Study design: Retrospective chart review of 142 paediatric CF patients from 2007 till 2011.
Results: Thirty eight children received stoss therapy and 37 children with vitamin D deﬁciency were not treated and served as a control group. The
stoss treated group had a signiﬁcant and sustained increase in 25-hydroxyvitamin D levels measured at 1, 3, 6 and 12 months post treatment
compared to controls (94.82±41.0 nmol/L, p=0.001; 81.54±24.6 nmol/L, p=0.001; 92.18±36.5 nmol/L, p=0.008 and 64.6±20.0 nmol/L,
p=0.006 respectively). At 12 months post intervention, the mean difference in vitamin D levels from baseline between the stoss treated group and
controls was signiﬁcant at 15 nmol/L compared to 5 nmol/L (p=0.038).
Conclusion: Stoss therapy effectively achieves and maintains levels of 25-hydroxyvitamin D greater than 75 nmol/L over 12 months.
© 2012 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic ﬁbrosis; Bone health; Vitamin D; Stoss therapy1. Introduction
Cystic fibrosis (CF), which is the most common genetic
life-limiting condition of European descent, is characterised by
progressive suppurative lung disease, pancreatic insufficiency and
nutritional impairment. Asmedian survival improves in individuals
with CF, many are developing long-term complications such as CF
related diabetes (CFRD) and bone disease. The aetiology of CF
bone disease is multi-factorial and includes malabsorption of fat
soluble vitamins D and K, poor nutrition, decreased physical
activity, glucocorticoid therapy, hypogonadism, chronic pulmo-
nary inflammation causing increased circulating cytokines and the
direct effect of the abnormal cystic fibrosis transmembrane
conductance regulator [1–6].
In bone, vitamin D has an important role in increasing the
absorption of intestinal calcium, stimulating osteoblastic activity⁎ Corresponding author. Tel.: +61 293821111; fax: +61 293821787.
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http://dx.doi.org/10.1016/j.jcf.2012.08.007.lishedand enhancing the production of osteoclasts [3]. Suboptimal
vitamin D levels may lead to reduced peak bone mass [7].
In individuals with CF, low vitamin D levels are of concern
because of the potential for chronic bone pain, chest deformity
and vertebral fractures [5]. Additionally, recent studies have
proposed possible immunomodulatory effects of vitamin D levels
on lung inflammation and pulmonary function [8,9] and linked
the degree of vitamin D deficiency with CF related diabetes [10].
Vitamin D has other potentially important roles such as effects on
muscle function, cardiovascular disease and cancer risk [8,9].
These findings suggest that improving levels of vitamin D in
individuals with CF is highly desirable. However, determining
the optimum level of vitamin D supplementation and the best
pharmacological strategy to achieve this in children is uncertain.
The US CF Foundation currently recommends a target
25-hydroxyvitamin D (25-OHD) level of 75–150 nmol/L
(30–60 ng/ml) [3], those falling below this level being
classified as vitamin D deficient. Recent European guidelines
have defined a 25-OHD level of below 50 nmol/L (20 ng/ml)by Elsevier B.V. All rights reserved.
Table 1
Replacement doses of cholecalciferol — stoss therapy.
25-Hydroxyvitamin D
level (nmol/L)
b3 years 3–12 years N12 years
≤25 200000 IU 400000 IU 600000 IU
25–50 150000 IU 350000 IU 500000 IU
50–75 100000 IU 200000 IU 300000 IU
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This recommendation is likely to be adopted by the Australian
Standards of Care currently under revision (Scott Bell— personal
communication).
The goal of vitamin D supplementation in the paediatric CF
population is to modify the potential risk for the developing CF
bone disease. There is an ongoing debate about the optimal
dosing regime and the formula of vitamin D which is most
efficacious. Many studies have demonstrated a lack of success
in maintaining an increased 25-OHD level despite supplemen-
tation. Boyle et al. [2] and Green et al. [3] showed that in adult
CF patients, treatment regimes based on US CF Foundation
guidelines for bone health, such as 50000 IU of ergocalciferol
(vitamin D2) weekly or twice weekly respectively, over
8 weeks, did not significantly increase 25-OHD levels. In
contrast, single high-dose vitamin D3 replacement therapy
(100000 IU–600000 IU (2500–15000 μg)), known as stoss
therapy (from the German “to push”), is an effective method for
treating vitamin D deficiency [12]. It involves a single oral or
intramuscular dose of vitamin D based on the age and vitamin
D level of the patient.
Oral cholecalciferol has been used safely and with success in
children with vitamin D deficient rickets [7], children with kidney
disease [8] and children with cystic fibrosis [16] with the
advantage of avoiding an injection. Similarly, single high-dose
(600000 IU) intramuscular cholecalciferol followed by oral
maintenance vitamin D has been shown to be safe in adult patients
with osteoporosis [12]. Potential risks of this approach however
may include hypervitaminosis D with resultant hypercalcaemia,
hyperphosphataemia, nausea and renal calculi [12].
The risk of hypervitaminosis D is low, however, Schlingmann
et al. [13] identified an autosomal recessive mutation in the
CYP24A1 gene, which encodes 25-hydroxyvitamin D 24-
hydroxylase (the key enzyme in 1,25-dihydroxyvitamin D3
degradation) in six children with idiopathic infantile hyper-
calcaemia and in four children who developed hypercalcaemia
post stoss therapy.
The aim of our study, therefore, was to investigate the safety
and efficacy of a single oral high-dose vitamin D3 (stoss
therapy) followed by maintenance oral vitamin D supplemen-
tation, in children with CF who were vitamin D deficient
(defined asb75 nmol/L).
2. Patients and methods
We performed a retrospective chart review of all children
attending the CF clinic at Sydney Children's Hospital, Randwick
between 2007 and 2011. As part of standard clinical care, all
children had annual fasting venous bloods for serum 25-OHD,
calcium, magnesium, phosphate, albumin and alkaline phospha-
tase. Children also underwent detailed medical and dietary
assessments and baseline anthropometry and pulmonary function
were measured. 25-OHD levels were analysed on the automated
Liason system utilising a chemoluminescent assay in the South
Eastern Area Laboratory Service at Sydney Children's Hospital.
Children with a serum 25-OHD level below 75 nmol/L were
considered for a trial of stoss therapy. The individual dose of stosstherapy was based on 25-OHD serum level and age as per
Table 1. This dosing regimen was chosen following consultation
with our Endocrinology department as it has previously been
shown to be safe in children and adults with cystic fibrosis,
rickets, kidney disease and vitamin D deficiency [7,8,12,14–17].
Stoss therapy was dispensed by the hospital pharmacy and
given as a single oral dose, under direct observation following
informed parental consent. Repeat serum levels were performed
according to a standard clinical care protocol at 1, 3 and
12 months post dose. In some patients a 6 month result was
obtained if the 3 month blood test had been omitted.
Children who were vitamin D deficient but did not receive
stoss therapy due to consultant or parental wishes were
assigned as the control group. Both the stoss therapy group
and controls were given routine dietary advice according to
current US and Australian guidelines for the prevention of
childhood vitamin D deficiency. These recommend a vitamin D
intake of 400 IU for those aged under one year and 800 IU for
those aged older than one year age group [1,3,5]. The control
group had serum 25-OHD, calcium, magnesium, phosphate,
albumin and alkaline phosphatase measured at annual review
and 12 months later as per standard clinical care.
3. Statistics
Data were analysed using the statistical software package
SPSS V19 (SPSS Inc., Chicago IL). Continuous data were
compared by paired t-tests and expressed as means±standard
deviation. A general linear model was used to test the
difference of means between those patients who received
stoss and the control group. For all analyses a p value of b0.05
was considered statistically significant.
4. Ethics
The Human Research Ethics Committee (HREC) at the
Sydney Children's Network approved this as a low risk study
(Approval number — LNR/11/SCHN/299).
Cholecalciferol is not commercially available in Australia so
the medication of Cholecalciferol Strong (50000 IU per tablet)
was obtained on an individual patient basis through the Special
Access Scheme via the Pharmacy Department of Sydney
Children's Hospital. All parents signed a consent form.
5. Results
Serum vitamin D and biochemical parameters were evalu-
ated in 142 children attending the CF annual review clinic.
There were an equal proportion of males and females with a
Fig. 1. Mean 25-hydroxyvitamin D levels of stoss treated patients over time.
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children had vitamin D levels less than 75 nmol/L. Of these, 42
received stoss therapy. Follow up blood investigations, as per
protocol, were available in 38. Two patients transitioned to
adult care and two patients had no or refused follow-up blood
tests. Of the 38 children with complete blood results at baseline,
17 (45%) had levels at the 1 month time point, 24 (63%) at 3 or
6 months and 30 (79%) at 12 months.
The control group consisted of thirty seven children and
12 month follow up results were available in 34 (92%).
The stoss and control groups had no significant differences
in the sex ratio, BMI percentage, genotype, pancreatic status,
calcium level and lung function. They did however differ in age
and initial 25-OHD levels (Table 2).6. Efficacy
Stoss therapy followed by maintenance 25-OHD resulted in a
significant rise in the mean 25-OHD level at all time points (Fig. 1,
Table 3). Although there was a decrease in the 25-OHD level at
12 months compared to the first month's result (p=0.006), levels
at 12 months remained significantly increased compared to the
pre-treatment level. Similarly, values at 1 month (p=0.049) and
combined 3–6 month data (p=0.027) were significantly elevated
above the target level of 75 nmol/L.
Individual changes in 25-OHD levels are shown in Fig. 2.
Despite individual variation in 25-OHD levels following stoss
therapy, the majority of patients had 25-OHD levels higher than
baseline when measured 12 months later.
The control group, had a mean 25-OHD level of 59.18±
11.9 nmol/L and 64.30±15.17 nmol/L at baseline and twelve
months respectively (p=0.132). Importantly, 82.4% of the
control group remained vitamin D deficient.
In children who had received stoss therapy, the mean
increase in 25-OHD level over the 12 month period was
15 nmol/L. This was significantly greater than the mean changeTable 2
Clinical characteristics of study population.
Control group Stoss treated group P value
Males, n (%) 18 (53%) 17 (45%) 0.249
Females, n (%) 16 (47%) 21 (55%)
Age (median) 6.5 12 0.009
0–9 years 24 (71%) 13 (34%)
N10 years 10 (29%) 25 (66%)
BMI percentage 55.4±27.7 43.84±28.1 0.084
Genotype 0.408
Delta F508/DF508 20 (59%) 22 (58%)
Delta F508/other 13 (38%) 9 (24%)
Other 1 (3%) 7 (18%)
Pancreatic insufficiency 30 (88%) 35 (92%) 0.870
25-Hydroxyvitamin D level
(nmol/L)
59.2±11.9 49.6±12.9 0.002
Season vitamin D measured
Summer/spring (%) 20 (59%) 18 (47%) 0.338
Autumn/winter (%) 14 (41%) 20 (53%) 0.238
Calcium (mmol/L) 2.35±0.09 2.34±0.07 0.63
Lung function (% FEV1) 98.7±16.5 93.5±12.5 0.22in the control group, who on average had a 5 nmol/L increase
in 25-OHD levels (p=0.038).7. Safety
There was no evidence of vitamin D toxicity, such as hyper-
calcaemia, hyperphosphataemia, nausea or renal calculi in the
stoss treated children (Table 4).8. Discussion
This study has demonstrated that a single, high-dose chole-
calciferol (vitamin D3) treatment in conjunction with mainte-
nance 25-OHD therapy can elevate and maintain an elevated
25-OHD level over a 12 month period in children with CF.
Stoss therapy effectively and safely achieves and maintains
25-OHD levels above 75 nmol/L in the majority of children
with CF. These results are likely to inform future decisions on
choosing target levels for vitamin D in CF.
We have also demonstrated a high prevalence of vitamin
deficiency (56%) in children with CF attending an Australian
CF Clinic (Sydney, 34°S latitude) where sunlight availability is
not a limiting factor. Furthermore, the average age of the
children with CF and vitamin D deficiency was 9.6 years which
overlaps with the critical period of peak bone mass accrual [24].
Vitamin D deficiency is commonly thought of as a spectrum,
from optimal vitamin D status, to inadequacy, through vitamin D
deficiency [19]. In this study we used a level of greater than
75 nmol/L to indicate optimum 25-OHD levels as recommended
by the US CF Foundation. We acknowledge that there are no
adult or paediatric randomised control studies assessing the effect
of 25-OHD levels on long term bone health, immune function,
cancer or cardiovascular risk in individuals with CF and that this
cut-off is arbitrary [11]. Indeed, recent European CF guidelines
have defined deficiency as a vitamin D level of b50 nmol/L,
which may reflect this paucity of CF specific evidence [11].Table 3
25-Hydroxyvitamin D levels over time with stoss therapy.
Time (months) 0 (n=38) 1 (n=17) 3 (n=13) 6 (n=11) 12 (n=30)
Mean (nmol/L) 49.6±12.9⁎ 94.82±41 81.54±24.6 92.18±36.5 64.6±20
P value 0.001 0.001 0.008 0.006
⁎ Values are mean±standard deviation.
Fig. 2. a. Mean 25-OHD levels of responders. b. Mean 25-OHD levels of partial
and non responders.
Table 4
Biochemical parameters in CF children who received stoss therapy.
Time (months) 0 1 3–6 12
Calcium
(mmol/L)
2.341±0.07 ⁎
n=37
2.346±0.07
n=16
2.373±0.08
n=20
2.342±0.088
n=26
Magnesium
(mmol/L)
0.877±0.05
n=35
0.860±0.06
n=16
0.883±0.056
n=19
0.882±0.07
n=24
Phosphate
(mmol/L)
1.54±0.21
n=37
1.580±0.20
n=16
1.539±0.19
n=20
1.5±0.23
n=26
Albumin
(g/L)
38.9±2.87
n=35
37.3±3.47
n=16
37.9±3.15
n=17
39±4.2
n=25
ALP (U/L) 228±69
n=34
252±81
n=16
239±89
n=17
225±93
n=25
⁎ Values are mean±standard deviation.
180 D. Shepherd et al. / Journal of Cystic Fibrosis 12 (2013) 177–182Similarly in Australia, Munns et al. [14] used a cut-off of
50 nmol/L to identify deficiency.
One practical argument for choosing the lower level of
50 nmol/L as the cut-off is that several research groups have
found it difficult to achieve 25-OHD levels above 75 nmol/L,
despite large doses and multiple vitamin D replacement regimens
[2,3,18]. Recent evidence based on optimal levels of PTH in
patients with CF indicates that higher levels (N87.5 nmol/L) are
required to maintain a PTH level below 50 pg/ml, as levels above
this are associated with increased bone resorption [20]. However
in studies in children with CF, the association of vitamin D and
PTH levels remains unclear [21-23]. Furthermore, the normal
mean 25-OHD level measured in large healthy paediatric control
groups is approximately 65 nmol/L [23].
Our study has demonstrated that higher levels of 25-OHD
are achievable through stoss therapy and that this approach is
practical, efficient and safe. Almost three-quarters (70%) of the
stoss treated group achieved a 25-OHD level above 75 nmol/L
during the 12-month follow up period. Therefore, we suggest
retaining the vitamin D target level at 75 nmol/L which is
supported by a recent update by the US CF Foundation [25].
Our findings are unique in that this study is the first to show
that optimum 25-OHD levels can be maintained for 12 months.
Previously, short-term improvements in 25-OHD levels have
been achieved in CF. Green et al. [15] showed that daily
treatment with 50000 IU of ergocalciferol for 28 days in a
paediatric CF population was effective in raising the 25-OHD
level above 75 nmol/L in 54% of patients. However, in most,
vitamin D levels were only measured 6 months post-treatment
and therefore long-term vitamin D sufficiency was not
determined. Interestingly, our study demonstrated that with
the intervention of a single high-dose cholecalciferol, 25-OHD
levels remained significantly elevated over all time points
compared to the pre-treatment level (Table 2) despite the
half-life of 25-OHD in serum being 22–28 days [26]. Cipriani
et al. [27] showed that in healthy adults aged 35–56 years old, a
single high dose (600000 IU) of vitamin D3 resulted in
significant increase in 25-OHD levels at 1 month and up to
3 months post dosing. Heanley et al. [28] showed that the
response of serum 25-OHD levels to oral vitamin D3 dose is
biphasic; initially a rapid increase occurs at low vitamin D3
levels and then a slower response at higher concentrations.
They hypothesised that the vitamin D3 is stored in body tissues
including fat and possibly muscle and is then released over
many months. A single oral dose of vitamin D3 (100000 IU) in
healthy adults had a half life of greater than 50 days, compared
to 20–30 days at lower physiological doses. Our study has
investigated not only the effect of a single high dose of vitamin
D3, but also in conjunction with ongoing routine maintenance
doses of vitamin D3. We hypothesise that this approach is likely
to have resulted in the prolongation of the elevation of serum
25-OHD levels seen in this study.
Not all patients who received stoss had an increase in serum
25-OHD levels in our study (Fig. 2b). This phenomenon has
been reported previously. In a study by Green et al. [15], the
non responder rate (defined as a decline or no change in
25-OHD) was 36%; in our study this was 13%. We had a
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70% compared to 54% in the Green et al. [15] study. Seventeen
percent of the stoss group had an elevation in serum 25-OHD,
but did not reach the 75 nmol/L cutoff and were labelled partial
responders. The five non responders had no difference in
genotype, pancreatic status or BMI percentage compared to the
responders. We hypothesise that these non responders probably
did not absorb the vitamin D3 dose. We have since changed our
protocol to administering the dose together with food and
pancreatic enzyme supplementation.
To our knowledge this is the first study to demonstrate a
significant long-term elevation of 25-OHD with vitamin D
supplementation over a 12 month period in children with CF.
The potential advantage of our replacement regimen is that it is
a single, directly observed dose, which achieves maximum
compliance. However, our study has several limitations, the
main being a lack of a matched placebo control group. Children
who formed the control group were vitamin D deficient
(b75 nmol/L) at baseline and although they did not receive
stoss therapy, they did receive CF specific dietary advice and
vitamin replacement therapy from our CF dietitian. Paired
serum 25-OHD in the control and stoss groups during the
subsequent twelve months would have helped address the
potential impact of seasonal variation, but would have involved
increased venipuncture for the control group. Several studies
have shown that vitamin D varies according to season, with the
highest readings being recorded during the summer months
[15,18]. In our study, the baseline and 12 month tests occurred
throughout the year. Green et al. [15] demonstrated that vitamin
D levels are highest when taken in summer and spring. The
difference in seasonal distribution between the stoss group (48%
in spring and summer) and control group (59% in spring and
summer) was not significant (p=0.338), indicating potential
seasonal bias is unlikely to account for the differences in baseline
and 12 month 25-OHD levels in the two groups.
Additionally, we did not quantitatively control for the actual
vitamin D maintenance therapy regimen or dietary advice given
to each group. All CF patients attending the clinic are provided
with dietary advice and vitamin replacement. However, it is
also possible that extra vitamin D was being administered from
other dietary sources such as fish oil supplements. Maintenance
vitamin D doses varied from 0 to 2440 IU/day in the stoss
group and 0 to 2000 IU/day in the control group. There was a
difference in the age of the two groups, with the stoss group
having a median age of 12 years and the control group with a
median age of 6.5 years (Table 2).
The strength of this study was that it was a pragmatic study
reflecting routine clinical practice. As such, it underscores the
feasibility of effectively and non-invasively raising vitamin D
levels in young children and adolescents with CF, during usual
outpatient care, to recommended optimal levels with long-term
benefit.
9. Conclusion
This study has shown that it is possible to obtain and sustain
vitamin D levels higher than 75 nmol/L with stoss therapy overa 12 month period and that stoss therapy is well tolerated in
children with CF. Importantly we did not detect any biochem-
ical abnormalities following administration. While we did not
undertake ultrasound examinations specifically for renal
calculi, no patient complained of renal pain.
We recognise that while we have shown it is possible to
achieve high serum levels of vitamin D with stoss, we have not
demonstrated an improved clinical outcome for CF bone
disease, the most important research question. Clearly what is
required is a prospective, properly designed study looking at
the effect of supplementation of vitamin D on serum levels and,
most importantly, on relevant clinical outcomes. Until then, the
debate on the appropriate cutoff level for vitamin D will
continue. This study has shown that it is possible to obtain and
sustain vitamin D levels higher than 75 nmol/L with stoss
therapy over a 12 month period and challenges the dogma that
these levels are difficult to achieve in children with CF.Acknowledgements
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